INTERESTED IN THIS RESEARCH?
Contact our analysts for inquiries, samples, and expert insights.
REPORT OUTLOOK
| Market Size | CAGR | Dominating Region |
|---|---|---|
| USD 384.82 Billion by 2030 | 10.60 % | North America |
| by Drug | by Therapeutic Area | by Patient | by Route of Administration |
|---|---|---|---|
|
|
|
|
SCOPE OF THE REPORT
Rare Disease Drug Market Overview
The global rare disease drug market is expected to grow from USD 190.10 Billion in 2023 to USD 384.82 Billion by 2030, at a Compound Annual Growth Rate (CAGR) of 10.60 % during the forecast period.
A “rare disease drug” is a pharmaceutical product that is specifically designed to diagnose, treat, or manage medical disorders classified as rare or orphan diseases. These illnesses are distinguished by their low frequency, affecting only a tiny proportion of the population. Given the small patient pool and the related hurdles, such as high research costs and regulatory complications, developing medications for rare illnesses need concentrated attention and incentives. Recognizing these specific problems, governments and regulatory bodies provide different incentives such as orphan medication designations, prolonged market exclusivity, and financial perks.
This drives pharmaceutical firms to invest in rare illness research and development. These treatments frequently employ a variety of therapeutic techniques, such as small molecules, biologics, gene therapies, and enzyme replacement therapies, that are customized to the unique needs of individuals suffering from rare illnesses. Biotechnology advancements, precision medicine, and increased awareness among healthcare professionals and advocacy groups all contribute to the ongoing progress in developing rare disease drugs, ultimately providing better treatment options for individuals suffering from these often debilitating and life-threatening conditions.
The implementation of orphan drug incentives by governments and regulatory agencies across the world has been critical in tackling the obstacles involved with developing treatments for rare diseases. These incentives, which include orphan medication designations, prolonged market exclusivity, and financial rewards, serve as a critical spur for pharmaceutical companies to dedicate resources to rare illness research and development.
Also, advances in biotechnology and genetic medicine have emerged as a significant driving factor. These advances allow for a more detailed understanding of the genetic and molecular basis of rare illnesses, paving the way for the development of targeted and customized therapeutics. The paradigm shift toward precision medicine aligns with the growing trend of personalizing therapies to individual patients’ particular genetic profiles, therefore boosting therapeutic efficacy while minimizing unwanted effects.
The growing awareness among healthcare professionals, patients, and advocacy organizations is propelling the rare illness medicine industry even further. more awareness leads to better diagnostic skills, early intervention measures, and more research funding. Particularly, patient advocacy groups are critical in driving research programs, campaigning for regulatory support, and encouraging cooperation between pharmaceutical companies and academics.
The rare disease drug industry plays a critical role in providing solutions for the particular medical needs of people with orphan or uncommon illnesses. Due to a lack of research and development, these illnesses, which are defined by their low prevalence, frequently lack appropriate therapies. Governmental incentives that encourage pharmaceutical firms to engage in rare illness research, such as prolonged market exclusivity and orphan medication designations, highlight the market’s significance. In addition, this market’s quest for biotechnology and precision medicine breakthroughs results in wider medical developments in addition to therapies for uncommon diseases.
| ATTRIBUTE | DETAILS |
| Study period | 2020-2030 |
| Base year | 2022 |
| Estimated year | 2023 |
| Forecasted year | 2023-2030 |
| Historical period | 2019-2021 |
| Unit | Value (USD Billion) Volume (Thousand Units) |
| Segmentation | By Drug, Therapeutic Area, Â Patient , Route of Administration and Region |
| Â
By Drug |
|
| Â
By Therapeutic Area |
|
| Â
By Patient |
|
| Â
By Route of Administration |
|
| Â
 By Region  |
|
Rare disease drug Market Segmentation Analysis
The Rare disease drug market offers a range of drug, including Biologics, Non-biologics. By Therapeutic Area the market is divided into Cancer, Blood-related Disorders, Central Nervous System (CNS), Respiratory Disorders, Musculoskeletal Disorders, Cardiovascular Disorders, Others. By Patient, the market is divided into up to Adult, Pediatric. By Route of Administration the market is classified into Oral, Injectable.
Based on drug, biologics segment dominating in the rare disease drug market. The dominance of the biologics category in the rare illness medicine industry represents a paradigm change in therapeutic approaches. Complex medications called biologics—made from living things or through biological processes—have shown a great deal of promise in treating uncommon disorders. These medications, which stand out for having a high specificity, are more accurate than conventional small-molecule medications in identifying the underlying causes of uncommon illnesses. When it comes to treating diseases like rare genetic abnormalities and unusual malignancies that have their roots in proteins or genetics, biologics have shown to be very beneficial.
Recombinant proteins, gene treatments, and monoclonal antibodies are a few prominent examples of the biologics class of drugs available for uncommon diseases. One specialized and targeted therapy option is provided by monoclonal antibodies, which can target certain proteins implicated in disease pathways. Another class of biologics known as gene therapy introduces genetic material to replace or correct defective genes, providing ground-breaking treatment for hereditary conditions that were previously thought to be incurable. Biologics are becoming more and more well-known as the market for medications for rare diseases changes, offering patients who are coping with these difficult medical conditions new and efficient treatment alternatives.
Improvements in biotechnological research and manufacturing techniques contribute to the dominance of biologics in the market for medications for uncommon diseases. These developments have made it possible to produce biologics that are more effective, have fewer adverse effects, and provide better results for patients. Regulatory agencies have also demonstrated a readiness to assist in the development and licensing of biologics for uncommon illnesses, acknowledging the potential of these treatments to fill gaps in the medical community.
Based on therapeutic area, cancer segment dominating in the rare disease drug market. The cancer segment is prominently positioned in the rare disease drug market, marking a substantial influence on therapeutic advancements for less common malignancies. Rare cancers, characterized by low prevalence and intricate characteristics, present distinct challenges in diagnosis and treatment. The emergence of targeted therapies and immunotherapies within the cancer therapeutic domain has demonstrated significant success, contributing to its heightened significance. Biologics, specifically monoclonal antibodies and immune checkpoint inhibitors, play a crucial role in treating rare cancers by precisely targeting specific proteins and leveraging the immune system’s capabilities.
The adoption of precision medicine stands out as a major driver in the cancer segment, enabling customized treatments based on the molecular features of individual tumors. This approach has proven effective in addressing the genetic diversity and heterogeneity inherent in rare cancers. Furthermore, advancements in genomic medicine have deepened our understanding of the underlying genetic mutations that drive these less common malignancies. As a result, ongoing research and innovations within the cancer segment continue to shape the landscape of rare disease drug development, offering tailored and effective therapeutic solutions for individuals confronting these challenging diseases.
Blood-related disorders, including rare blood cancers and genetic blood disorders, are a key focus, driving progress in hematological treatments. Central Nervous System (CNS) disorders, encompassing rare neurological conditions, spur research towards innovative solutions for brain and spinal cord disorders. Respiratory disorders in the rare disease space, such as pulmonary hypertension, require targeted therapies. Musculoskeletal disorders, addressing rare genetic and degenerative conditions, propel the development of treatments for skeletal and muscular abnormalities. Cardiovascular disorders in the rare disease realm target uncommon heart conditions, often necessitating specialized interventions.
Rare Disease Drug Market Dynamics
Driver
New technologies like gene editing and next-generation sequencing are driving rare disease drug market.
Next-generation sequencing (NGS) and gene editing are two of the most innovative technologies driving the market shift for drugs for rare diseases. The precision with which genes may be altered has been transformed by gene editing technologies like CRISPR-Cas9, providing previously unheard-of possibilities to treat the underlying genetic origins of rare diseases. This focused strategy has a lot of promise, especially for uncommon genetic illnesses when the condition is caused by certain gene abnormalities.
The genetic complexity of rare diseases is mostly unraveled through next-generation sequencing. With the use of this cutting-edge genomic technology, a person’s DNA may be quickly and thoroughly analyzed, making it easier to find uncommon genetic mutations and variations that are linked to a variety of ailments. In addition to speeding up the diagnostic process, next-generation sequencing (NGS) improves our knowledge of the genetic underpinnings of uncommon diseases, which informs the creation of more specialized and successful treatment plans.
The process of discovering and creating drugs for rare diseases has been significantly accelerated by these technologies. Through enhanced comprehension of the underlying molecular and genetic processes, gene editing and next-generation sequencing (NGS) enable scientists to identify new targets for therapeutic intervention. They also make it easier to create personalized medications and gene treatments that are specifically designed to target the genetic profiles of people who have rare diseases.
Drug trials for rare diseases have been expedited by the combination of these technologies. More effective and focused clinical trial designs are made possible by advances in diagnostics, patient classification based on genetic markers, and improved therapy response tracking.
Restraint
Lack of awareness and diagnosis can impede the rare disease drug market during the forecast period.
The lack of awareness and underdiagnosis appears as a significant impediment to the expected growth and prosperity of the rare disease medication market throughout the predicted period. Rare diseases are unknown to both healthcare professionals and the general population due to their low prevalence, resulting in delayed or missed diagnosis and delaying early treatment start. Individuals suffering from rare diseases may face protracted periods of uncertainty, misdiagnosis, or poor therapy, exacerbating the severity of their conditions.
This lack of understanding goes beyond the medical community to regulatory authorities, pharmaceutical corporations, and funding organizations, impacting resource allocation and rare disease research programs. Inadequate knowledge of the frequency, symptoms, and genetic basis of many diseases impedes the development of targeted medicines and delays regulatory approval.
Furthermore, the rarity and variability of rare diseases make it difficult to develop conventional diagnostic criteria, resulting in a lack of consistency in clinical practice. This intricacy hinders the selection of eligible individuals for clinical trials, affecting the whole landscape of rare disease medication research and development.
Opportunities
Personalized medicine is creating new opportunities for the rare disease drug market.
Personalized medicine, defined as the personalization of medical therapy based on individual patient characteristics, is fundamentally changing the landscape of the rare disease medication industry, bringing innovative and attractive options. Given the unique heterogeneity inherent in rare diseases, which is frequently caused by distinct genetic mutations or variants, personalized therapy is especially relevant in this context. Advances in genomics and molecular diagnostics have allowed for a better understanding of the genetic basis of rare diseases, paving the way for more precise and focused treatment approaches. Personalized medicine improves diagnosis accuracy in the area of rare diseases by discovering unique genetic variants or biomarkers related with an individual’s ailment. This enables the creation of therapeutics that directly address the underlying cause of the disease, perhaps leading to more effective and efficient treatments.
In addition, personalized medicine is critical in developing targeted medicines, which include gene therapies and biologics tailored to address the precise genetic or molecular anomalies that cause uncommon illnesses. This method departs from the one-size-fits-all strategy by providing tailored treatment options that take into consideration each patient’s unique genetic composition. The capacity to distinguish between responders and non-responders to certain therapies is critical in enhancing therapeutic outcomes and reducing unwanted side effects.
Personalized medicine helps to precise patient stratification in clinical trials, ensuring that participants have the exact genetic markers or traits relevant to the experimental therapy. This not only improves clinical trial design efficiency, but it also increases the possibility of establishing treatment efficacy.
Rare Disease Drug Market Trends
-
The rare disease drug market has seen a surge in the development of gene therapies and advanced biologics. These innovative treatments aim to address the root causes of rare genetic disorders and provide more targeted and effective solutions.
-
Increasing emphasis on precision medicine has been a notable trend. Advancements in genomics and molecular diagnostics have enabled a more personalized approach to treatment, allowing for therapies tailored to the specific genetic makeup of individuals with rare diseases.
-
Next-generation sequencing technologies have continued to evolve, contributing to a deeper understanding of the genetic complexities of rare diseases. NGS plays a crucial role in rapid and comprehensive genetic analysis, aiding in diagnosis and informing treatment strategies.
-
The integration of advanced technologies, such as wearable devices and digital health solutions, into clinical trials has improved patient monitoring and data collection, enhancing the efficiency of rare disease drug development.
-
AI is playing an increasingly important role in drug discovery and development for rare diseases. By analyzing large datasets of genetic and clinical data, AI algorithms can identify potential drug targets, predict patient response to treatment, and accelerate the development process.
-
The rise of personalized medicine is transforming the way rare diseases are diagnosed and treated. Genetic testing and other diagnostic tools are helping identify the specific mutations causing individual cases, allowing for targeted therapies with improved efficacy and fewer side effects.
Competitive Landscape
The competitive landscape of the rare disease drug market was dynamic, with several prominent companies competing to provide innovative and advanced rare disease drug solutions.
- Seagen Inc.
- Novartis AG
- Vertex Pharmaceuticals Incorporated
- Pfizer Inc.
- Eli Lilly and Company
- Merck
- Bayer AG
- Roche
- Johnson & Johnson
- GlaxoSmithKline plc.
- Pharmacyclics LLC
- Bristol-Myers Squibb
- BioMarin
- AbbVie Inc.
- AstraZeneca plc
- Hoffman-La-Roche Ltd.
- Biogen
- Amgen Inc.
- Sanofi
- Alexion Pharmaceuticals
Recent Developments:
December 27, 2023: Eli Lilly and Company (NYSE: LLY) announced the completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.
December 6, 2023: Novartis announced that the U.S. Food and Drug Administration (FDA) approved Fabhalta® (iptacopan) as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)1. Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH]).
Regional Analysis
North America accounted for the largest market in the rare disease drug market. North America accounted for the 31 % market share of the global market value. North America consistently holds a pivotal position in the rare disease drug sector, driven by various factors. The region boasts a well-established healthcare infrastructure, featuring advanced research facilities, esteemed academic institutions, and pharmaceutical companies leading the charge in rare disease research and drug development. Additionally, North America benefits from a robust regulatory framework, exemplified by agencies like the U.S. Food and Drug Administration (FDA), which offers efficient processes for orphan drug designations and approvals. This regulatory support acts as a significant incentive for pharmaceutical companies to channel investments into the development of therapies for rare diseases.
The documented prevalence of rare diseases in North America, coupled with an increasing awareness among healthcare professionals and the public, has catalyzed heightened research initiatives and clinical trials for rare disease drugs. The region’s economic strength and substantial healthcare expenditure further contribute to the accessibility of cutting-edge medical technologies, including next-generation sequencing and gene editing tools. These technological advancements, readily available in North America, play a crucial role in facilitating state-of-the-art research and development endeavors in the field of rare diseases.
The market is growing in Europe due to factors including strict regulatory frameworks, a well-established healthcare infrastructure, and an increase in the occurrence of rare illnesses. Innovation has been fostered by greater collaboration between academics, pharmaceutical corporations, and advocacy organizations in European countries that place a significant focus on research and development. The market is further stimulated by the European Union’s Orphan Medicinal Regulation, which offers incentives for medicinal development. The Asia-Pacific region presents a dynamic landscape for rare disease medication markets due to changing healthcare systems and a growing population. Increased funding has resulted from the implementation of particular regulations and incentives for orphan medication research by nations such as Japan. The Asia-Pacific market gains from rising rare illness awareness and advancements in diagnosis. Nonetheless, obstacles encompass heterogeneous regulatory environments and disparities in healthcare accessibility among nations.
Target Audience for Rare disease drug Market
- Pharmaceutical Companies
- Biotechnology Companies
- Research Institutions
- Academic Institutions
- Healthcare Professionals
- Regulatory Authorities
- Government Health Agencies
- Investors and Financial Institutions
- Clinical Research Organizations (CROs)
- Genetic Testing and Diagnostic Companies
- Contract Manufacturing Organizations (CMOs)
- Market Research and Consulting Firms
- Insurance Companies
- Rare Disease Therapeutic Centers
- Drug Development and Clinical Trial Professionals
Import & Export Data for Rare disease drug Market
Exactitude consultancy provides import and export data for the recent years. It also offers insights on production and consumption volume of the product. Understanding the import and export data is pivotal for any player in the rare disease drug market. This knowledge equips businesses with strategic advantages, such as:
- Identifying emerging markets with untapped potential.
- Adapting supply chain strategies to optimize cost-efficiency and market responsiveness.
- Navigating competition by assessing major players’ trade dynamics.
Key insights
-
Trade volume trends: our report dissects import and export data spanning the last five years to reveal crucial trends and growth patterns within the global rare disease drug market. This data-driven exploration empowers readers with a deep understanding of the market’s trajectory.
-
Market players: gain insights into the leading players driving the rare disease drug trade. From established giants to emerging contenders, our analysis highlights the key contributors to the import and export landscape.
-
Geographical dynamics: delve into the geographical distribution of trade activities. Uncover which regions dominate exports and which ones hold the reins on imports, painting a comprehensive picture of the industry’s global footprint.
-
Product breakdown: by segmenting data based on rare disease drug types –– we provide a granular view of trade preferences and shifts, enabling businesses to align strategies with the evolving technological landscape.
Import and export data is crucial in reports as it offers insights into global market trends, identifies emerging opportunities, and informs supply chain management. By analyzing trade flows, businesses can make informed decisions, manage risks, and tailor strategies to changing demand. This data aids government in policy formulation and trade negotiations, while investors use it to assess market potential. Moreover, import and export data contributes to economic indicators, influences product innovation, and promotes transparency in international trade, making it an essential component for comprehensive and informed analyses.
Segments Covered in the Rare disease drug Market Report
Rare disease drug Market by Drug
- Biologics
- Non-biologics
Rare disease drug Market by Therapeutic Area
- Cancer
- Blood-related Disorders
- Central Nervous System (CNS)
- Respiratory Disorders
- Musculoskeletal Disorders
- Cardiovascular Disorders
- Others
Rare disease drug Market by Patient
- Adult
- Pediatric
Rare disease drug Market by Route of Administration
- Oral
- Injectable
Rare disease drug Market by Region
-
- North America
- Europe
- Asia Pacific
- South America
- Middle East and Africa
Key Question Answered
- What is the expected growth rate of the rare disease drug market over the next 7 years?
- Who are the major players in the rare disease drug market and what is their market share?
- What are the Application industries driving market demand and what is their outlook?
- What are the opportunities for growth in emerging markets such as Asia-Pacific, the middle east, and Africa?
- How is the economic environment affecting the rare disease drug market, including factors such as interest rates, inflation, and exchange rates?
- What is the expected impact of government policies and regulations on the rare disease drug market?
- What is the current and forecasted size and growth rate of the global rare disease drug market?
- What are the key drivers of growth in the rare disease drug market?
- Who are the major players in the market and what is their market share?
- What are the distribution channels and supply chain dynamics in the rare disease drug market?
- What are the technological advancements and innovations in the rare disease drug market and their impact on product development and growth?
- What are the regulatory considerations and their impact on the market?
- What are the challenges faced by players in the rare disease drug market and how are they addressing these challenges?
- What are the opportunities for growth and expansion in the rare disease drug market?
- What are the product offerings and specifications of leading players in the market?
Table of Content
- INTRODUCTION
- MARKET DEFINITION
- MARKET SEGMENTATION
- RESEARCH TIMELINES
- ASSUMPTIONS AND LIMITATIONS
- RESEARCH METHODOLOGY
- DATA MINING
- SECONDARY RESEARCH
- PRIMARY RESEARCH
- SUBJECT-MATTER EXPERTS’ ADVICE
- QUALITY CHECKS
- FINAL REVIEW
- DATA TRIANGULATION
- BOTTOM-UP APPROACH
- TOP-DOWN APPROACH
- RESEARCH FLOW
- DATA SOURCES
- DATA MINING
- EXECUTIVE SUMMARY
- MARKET OVERVIEW
- GLOBAL RARE DISEASE DRUG MARKET OUTLOOK
- MARKET DRIVERS
- MARKET RESTRAINTS
- MARKET OPPORTUNITIES
- IMPACT OF COVID-19 ON RARE DISEASE DRUG MARKET
- PORTER’S FIVE FORCES MODEL
- THREAT FROM NEW ENTRANTS
- THREAT FROM SUBSTITUTES
- BARGAINING POWER OF SUPPLIERS
- BARGAINING POWER OF CUSTOMERS
- DEGREE OF COMPETITION
- ROUTE OF ADMINISTRATION VALUE CHAIN ANALYSIS
- GLOBAL RARE DISEASE DRUG MARKET OUTLOOK
- GLOBAL RARE DISEASE DRUG MARKET BY DRUG, 2020-2030, (USD BILLION) (THOUSAND UNITS)
- BIOLOGICS
- NON-BIOLOGICS
- GLOBAL RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA, 2020-2030, (USD BILLION) (THOUSAND UNITS)
- CANCER
- BLOOD-RELATED DISORDERS
- CENTRAL NERVOUS SYSTEM (CNS)
- RESPIRATORY DISORDERS
- MUSCULOSKELETAL DISORDERS
- CARDIOVASCULAR DISORDERS
- OTHERS
- GLOBAL RARE DISEASE DRUG MARKET BY PATIENT, 2020-2030, (USD BILLION) (THOUSAND UNITS)
- ADULT
- PEDIATRIC
- GLOBAL RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION, 2020-2030, (USD BILLION) (THOUSAND UNITS)
- ORAL
- INJECTABLE
- GLOBAL RARE DISEASE DRUG MARKET BY REGION, 2020-2030, (USD BILLION) (THOUSAND UNITS)
- NORTH AMERICA
- US
- CANADA
- MEXICO
- SOUTH AMERICA
- BRAZIL
- ARGENTINA
- COLOMBIA
- REST OF SOUTH AMERICA
- EUROPE
- GERMANY
- UK
- FRANCE
- ITALY
- SPAIN
- RUSSIA
- REST OF EUROPE
- ASIA PACIFIC
- INDIA
- CHINA
- JAPAN
- SOUTH KOREA
- AUSTRALIA
- SOUTH-EAST ASIA
- REST OF ASIA PACIFIC
- MIDDLE EAST AND AFRICA
- UAE
- SAUDI ARABIA
- SOUTH AFRICA
- REST OF MIDDLE EAST AND AFRICA
- NORTH AMERICA
- COMPANY PROFILES*
Â
(BUSINESS OVERVIEW, COMPANY SNAPSHOT, PRODUCT OFFERED, RECENT DEVELOPMENTS)
- SEAGEN INC.
- NOVARTIS AG
- VERTEX PHARMACEUTICALS INCORPORATED
- PFIZER INC.
- ELI LILLY AND COMPANY
- MERCK
- BAYER AG
- ROCHE
- JOHNSON & JOHNSON
- GLAXOSMITHKLINE PLC.
- PHARMACYCLICS LLC
- BRISTOL-MYERS SQUIBB
- BIOMARIN
- ABBVIE INC.
- ASTRAZENECA PLC
- HOFFMAN-LA-ROCHE LTD.
- BIOGEN
- AMGEN INC.
- SANOFI
- ALEXION PHARMACEUTICALSÂ Â Â Â Â Â Â *THE COMPANY LIST IS INDICATIVE
LIST OF TABLES
TABLE 1Â Â Â Â Â GLOBAL RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 2Â Â Â Â Â GLOBAL RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 3Â Â Â Â Â GLOBAL RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 4Â Â Â Â Â GLOBAL RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 5Â Â Â Â Â GLOBAL RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 6Â Â Â Â Â GLOBAL RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 7Â Â Â Â Â GLOBAL RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 8Â Â Â Â Â GLOBAL RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 9Â Â Â Â Â GLOBAL RARE DISEASE DRUG MARKET BY REGION (USD BILLION) 2020-2030
TABLE 10Â Â Â GLOBAL RARE DISEASE DRUG MARKET BY REGION (THOUSAND UNITS) 2020-2030
TABLE 11Â Â Â NORTH AMERICA RARE DISEASE DRUG MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 12Â Â Â NORTH AMERICA RARE DISEASE DRUG MARKET BY COUNTRY (THOUSAND UNITS) 2020-2030
TABLE 13Â Â Â NORTH AMERICA RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 14Â Â Â NORTH AMERICA RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 15Â Â Â NORTH AMERICA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 16Â Â Â NORTH AMERICA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 17Â Â Â NORTH AMERICA RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 18Â Â Â NORTH AMERICA RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 19Â Â Â NORTH AMERICA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 20Â Â Â NORTH AMERICA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 21Â Â Â US RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 22Â Â Â US RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 23Â Â Â US RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 24Â Â Â US RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 25Â Â Â US RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 26Â Â Â US RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 27Â Â Â US RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 28Â Â Â US RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 29Â Â Â CANADA RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 30Â Â Â CANADA RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 31Â Â Â CANADA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 32Â Â Â CANADA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 33Â Â Â CANADA RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 34Â Â Â CANADA RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 35Â Â Â CANADA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 36Â Â Â CANADA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 37Â Â Â MEXICO RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 38Â Â Â MEXICO RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 39Â Â Â MEXICO RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 40Â Â Â MEXICO RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 41Â Â Â MEXICO RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 42Â Â Â MEXICO RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 43Â Â Â MEXICO RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 44Â Â Â MEXICO RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 45Â Â Â SOUTH AMERICA RARE DISEASE DRUG MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 46Â Â Â SOUTH AMERICA RARE DISEASE DRUG MARKET BY COUNTRY (THOUSAND UNITS) 2020-2030
TABLE 47Â Â Â SOUTH AMERICA RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 48Â Â Â SOUTH AMERICA RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 49Â Â Â SOUTH AMERICA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 50Â Â Â SOUTH AMERICA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 51Â Â Â SOUTH AMERICA RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 52Â Â Â SOUTH AMERICA RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 53Â Â Â SOUTH AMERICA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 54Â Â Â SOUTH AMERICA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 55Â Â Â BRAZIL RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 56Â Â Â BRAZIL RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 57Â Â Â BRAZIL RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 58Â Â Â BRAZIL RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 59Â Â Â BRAZIL RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 60Â Â Â BRAZIL RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 61Â Â Â BRAZIL RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 62Â Â Â BRAZIL RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 63Â Â Â ARGENTINA RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 64Â Â Â ARGENTINA RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 65Â Â Â ARGENTINA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 66Â Â Â ARGENTINA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 67Â Â Â ARGENTINA RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 68Â Â Â ARGENTINA RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 69Â Â Â ARGENTINA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 70Â Â Â ARGENTINA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 71Â Â Â COLOMBIA RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 72Â Â Â COLOMBIA RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 73Â Â Â COLOMBIA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 74Â Â Â COLOMBIA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 75Â Â Â COLOMBIA RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 76Â Â Â COLOMBIA RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 77Â Â Â COLOMBIA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 78Â Â Â COLOMBIA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 79Â Â Â REST OF SOUTH AMERICA RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 80Â Â Â REST OF SOUTH AMERICA RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 81Â Â Â REST OF SOUTH AMERICA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 82Â Â Â REST OF SOUTH AMERICA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 83Â Â Â REST OF SOUTH AMERICA RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 84Â Â Â REST OF SOUTH AMERICA RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 85Â Â Â REST OF SOUTH AMERICA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 86Â Â Â REST OF SOUTH AMERICA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 87Â Â Â ASIA-PACIFIC RARE DISEASE DRUG MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 88Â Â Â ASIA-PACIFIC RARE DISEASE DRUG MARKET BY COUNTRY (THOUSAND UNITS) 2020-2030
TABLE 89Â Â Â ASIA-PACIFIC RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 90Â Â Â ASIA-PACIFIC RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 91Â Â Â ASIA-PACIFIC RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 92Â Â Â ASIA-PACIFIC RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 93Â Â Â ASIA-PACIFIC RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 94Â Â Â ASIA-PACIFIC RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 95Â Â Â ASIA-PACIFIC RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 96Â Â Â ASIA-PACIFIC RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 97Â Â Â INDIA RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 98Â Â Â INDIA RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 99Â Â Â INDIA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 100Â INDIA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 101Â INDIA RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 102Â INDIA RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 103Â INDIA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 104Â INDIA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 105Â CHINA RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 106Â CHINA RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 107Â CHINA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 108Â CHINA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 109Â CHINA RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 110Â CHINA RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 111Â CHINA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 112Â CHINA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 113Â JAPAN RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 114Â JAPAN RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 115Â JAPAN RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 116Â JAPAN RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 117Â JAPAN RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 118Â JAPAN RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 119Â JAPAN RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 120Â JAPAN RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 121Â SOUTH KOREA RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 122Â SOUTH KOREA RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 123Â SOUTH KOREA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 124Â SOUTH KOREA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 125Â SOUTH KOREA RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 126Â SOUTH KOREA RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 127Â SOUTH KOREA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 128Â SOUTH KOREA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 129Â AUSTRALIA RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 130Â AUSTRALIA RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 131Â AUSTRALIA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 132Â AUSTRALIA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 133Â AUSTRALIA RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 134Â AUSTRALIA RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 135Â AUSTRALIA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 136Â AUSTRALIA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 137Â SOUTH-EAST ASIA RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 138Â SOUTH-EAST ASIA RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 139Â SOUTH-EAST ASIA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 140Â SOUTH-EAST ASIA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 141Â SOUTH-EAST ASIA RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 142Â SOUTH-EAST ASIA RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 143Â SOUTH-EAST ASIA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 144Â SOUTH-EAST ASIA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 145Â REST OF ASIA PACIFIC RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 146Â REST OF ASIA PACIFIC RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 147Â REST OF ASIA PACIFIC RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 148Â REST OF ASIA PACIFIC RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 149Â REST OF ASIA PACIFIC RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 150Â REST OF ASIA PACIFIC RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 151Â REST OF ASIA PACIFIC RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 152Â REST OF ASIA PACIFIC RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 153Â EUROPE RARE DISEASE DRUG MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 154Â EUROPE RARE DISEASE DRUG MARKET BY COUNTRY (THOUSAND UNITS) 2020-2030
TABLE 155Â EUROPE RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 156Â EUROPE RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 157Â EUROPE RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 158Â EUROPE RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 159Â EUROPE RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 160Â EUROPE RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 161Â EUROPE RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 162Â EUROPE RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 163Â GERMANY RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 164Â GERMANY RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 165Â GERMANY RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 166Â GERMANY RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 167Â GERMANY RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 168Â GERMANY RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 169Â GERMANY RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 170Â GERMANY RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 171Â UK RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 172Â UK RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 173Â UK RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 174Â UK RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 175Â UK RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 176Â UK RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 177Â UK RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 178Â UK RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 179Â FRANCE RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 180Â FRANCE RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 181Â FRANCE RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 182Â FRANCE RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 183Â FRANCE RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 184Â FRANCE RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 185Â FRANCE RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 186Â FRANCE RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 187Â ITALY RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 188Â ITALY RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 189Â ITALY RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 190Â ITALY RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 191Â ITALY RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 192Â ITALY RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 193Â ITALY RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 194Â ITALY RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 195Â SPAIN RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 196Â SPAIN RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 197Â SPAIN RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 198Â SPAIN RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 199Â SPAIN RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 200Â SPAIN RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 201Â SPAIN RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 202Â SPAIN RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 203Â RUSSIA RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 204Â RUSSIA RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 205Â RUSSIA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 206Â RUSSIA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 207Â RUSSIA RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 208Â RUSSIA RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 209Â RUSSIA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 210Â RUSSIA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 211Â REST OF EUROPE RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 212Â REST OF EUROPE RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 213Â REST OF EUROPE RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 214Â REST OF EUROPE RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 215Â REST OF EUROPE RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 216Â REST OF EUROPE RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 217Â REST OF EUROPE RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 218Â REST OF EUROPE RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 219Â MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 220Â MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY COUNTRY (THOUSAND UNITS) 2020-2030
TABLE 221Â MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 222Â MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 223Â MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 224Â MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 225Â MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 226Â MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 227Â MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 228Â MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 229Â UAE RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 230Â UAE RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 231Â UAE RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 232Â UAE RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 233Â UAE RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 234Â UAE RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 235Â UAE RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 236Â UAE RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 237Â SAUDI ARABIA RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 238Â SAUDI ARABIA RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 239Â SAUDI ARABIA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 240Â SAUDI ARABIA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 241Â SAUDI ARABIA RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 242Â SAUDI ARABIA RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 243Â SAUDI ARABIA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 244Â SAUDI ARABIA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 245Â SOUTH AFRICA RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 246Â SOUTH AFRICA RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 247Â SOUTH AFRICA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 248Â SOUTH AFRICA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 249Â SOUTH AFRICA RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 250Â SOUTH AFRICA RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 251Â SOUTH AFRICA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 252Â SOUTH AFRICA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
TABLE 253Â REST OF MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
TABLE 254Â REST OF MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY DRUG (THOUSAND UNITS) 2020-2030
TABLE 255Â REST OF MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
TABLE 256Â REST OF MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (THOUSAND UNITS) 2020-2030
TABLE 257Â REST OF MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
TABLE 258Â REST OF MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY PATIENT (THOUSAND UNITS) 2020-2030
TABLE 259Â REST OF MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
TABLE 260Â REST OF MIDDLE EAST AND AFRICA RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (THOUSAND UNITS) 2020-2030
LIST OF FIGURES
FIGURE 1Â Â Â MARKET DYNAMICS
FIGURE 2Â Â Â MARKET SEGMENTATION
FIGURE 3Â Â Â REPORT TIMELINES: YEARS CONSIDERED
FIGURE 4Â Â Â DATA TRIANGULATION
FIGURE 5Â Â Â BOTTOM-UP APPROACH
FIGURE 6Â Â Â TOP-DOWN APPROACH
FIGURE 7Â Â Â RESEARCH FLOW
FIGURE 8Â Â Â GLOBAL RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2020-2030
FIGURE 9Â Â Â GLOBAL RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2020-2030
FIGURE 10 GLOBAL RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2020-2030
FIGURE 11 GLOBAL RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2030
FIGURE 12 GLOBAL RARE DISEASE DRUG MARKET BY REGION (USD BILLION) 2020-2030
FIGURE 13 PORTER’S FIVE FORCES MODEL
FIGURE 14 GLOBAL RARE DISEASE DRUG MARKET BY DRUG (USD BILLION) 2022
FIGURE 15 GLOBAL RARE DISEASE DRUG MARKET BY THERAPEUTIC AREA (USD BILLION) 2022
FIGURE 16 GLOBAL RARE DISEASE DRUG MARKET BY PATIENT (USD BILLION) 2022
FIGURE 17 GLOBAL RARE DISEASE DRUG MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2022
FIGURE 18 GLOBAL RARE DISEASE DRUG MARKET BY REGION (USD BILLION) 2022
FIGURE 19 MARKET SHARE ANALYSIS
FIGURE 20 SEAGEN INC.: COMPANY SNAPSHOT
FIGURE 21 NOVARTIS AG: COMPANY SNAPSHOT
FIGURE 22 VERTEX PHARMACEUTICALS INCORPORATED: COMPANY SNAPSHOT
FIGURE 23 PFIZER INC.: COMPANY SNAPSHOT
FIGURE 24 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
FIGURE 25 MERCK: COMPANY SNAPSHOT
FIGURE 26 BAYER AG: COMPANY SNAPSHOT
FIGURE 27 ROCHE: COMPANY SNAPSHOT
FIGURE 28 JOHNSON & JOHNSON: COMPANY SNAPSHOT
FIGURE 29 GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
FIGURE 30 PHARMACYCLICS LLC: COMPANY SNAPSHOT
FIGURE 31 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
FIGURE 32 BIOMARIN: COMPANY SNAPSHOT
FIGURE 33 ABBVIE INC.: COMPANY SNAPSHOT
FIGURE 34 ASTRAZENECA PLC: COMPANY SNAPSHOT
FIGURE 35 F. HOFFMAN-LA-ROCHE LTD.: COMPANY SNAPSHOT
FIGURE 36 BIOGEN: COMPANY SNAPSHOT
FIGURE 37 AMGEN INC.: COMPANY SNAPSHOT
FIGURE 38 SANOFI: COMPANY SNAPSHOT
FIGURE 39 ALEXION PHARMACEUTICALS: COMPANY SNAPSHOT
FAQ
The global rare disease drug market is expected to grow from USD 190.10 Billion in 2023 to USD 384.82 Billion by 2030, at a Compound Annual Growth Rate (CAGR) of 10.60 % during the forecast period.
North America accounted for the largest market in the rare disease drug market. North America accounted for 31 % market share of the global market value.
Seagen Inc., Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., Eli Lilly and Company, Merck, Bayer AG, Roche, Johnson & Johnson, GlaxoSmithKline plc., Pharmacyclics LLC, Bristol-Myers Squibb, BioMarin, AbbVie Inc., AstraZeneca plc, F. Hoffman-La-Roche Ltd., Biogen, Amgen Inc., Sanofi, Alexion Pharmaceuticals
The potential for increased government incentives and regulatory support for orphan drug development, encouraging pharmaceutical companies to invest in research and development for rare diseases. Additionally, advancements in precision medicine and gene therapies present new avenues for developing targeted and innovative treatments, offering promising opportunities to address the specific challenges posed by rare diseases.
In-Depth Database
Our Report’s database covers almost all topics of all regions over the Globe.
Recognised Publishing Sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales
support.
Safe & Secure
Complete secure payment
process.